Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Hacioglu, Muhammet; Kostek, Osman; Karabulut, Senem; Tastekin, Didem; SEZGİN GÖKSU, SEMA; Alandag, Celal; Akagunduz, Baran; Bilgetekin, Irem; Caner, BURCU; ŞAHİN, AHMET; Yildiz, Birol; Kose, Fatih; Kaplan, Muhammet; Gulmez, Ahmet; DOĞAN, ENDER; Guven, Deniz; Gurbuz, Mustafa; Ergun, Yakup; KARAAĞAÇ, MUSTAFA; Demiray, Atike; Turker, Sema; Sakalar, Teoman; Ozkul, Ozlem; Telli, Tugba; Sahin, Suleyman; KILIÇKAP, SAADETTİN; Bilici, Ahmet; ERDOĞAN, BÜLENT; ÇİÇİN, İRFAN

Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., ...Daha Fazla

JOURNAL OF BUON, cilt.25, sa.4, ss.1897-1903, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 25 Sayı: 4
Basım Tarihi: 2020
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
Sayfa Sayıları: ss.1897-1903
Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the secondor third-line setting.